Cleerly
Cleerly is a digital healthcare company transforming the way clinicians approach the treatment of heart disease. We design intelligent clinical technologies to help clinicians precisely identify and define atherosclerosis earlier, so they can provide personalized, life-saving treatment plans for all patients throughout their care continuum. We measure atherosclerosis, plaque build-up in the heart's arteries, not indirect markers such as risk factors and symptoms of the disease. Our AI-enabled digital care pathway offers simpler, faster, more accurate heart disease diagnostics and reporting that's tailored to each stakeholder, improving overall clinical and financial outcomes. Cleerly empowers providers to go beyond traditional measures of heart disease by analyzing, characterizing, and quantifying types of plaque, so they can more accurately determine a patient's risk of heart attack and develop a treatment plan to improve heart health.
Learn more
OMS Trace Analytics
Enhance value-based care with the OMS Trace Analytics® cloud platform for the analysis and reporting of critical cardiovascular metrics. Increasingly reimbursement is being tied to value. For example, for the performance year 2018, 60% of Medicare reimbursements are being linked to quality under the Quality Payment Program. The need for a discrete data and evidence-based quality reporting solution to measure, target and improve your quality program is more critical than ever. The OMS Trace Analytics® cloud platform is designed to deliver deep clinical insights for cardiovascular diseases with dedicated dashboards for leading cardiovascular diseases like Hypertension, Dyslipidemia, Atrial Fibrillation, Heart Failure, Coronary Artery Disease and Peripheral Artery Disease.
Learn more
HeartFlow
HeartFlow's non-invasive personalized cardiac test provides unprecedented visualization of each patient's coronary arteries, enabling physicians to create more effective treatment plans for their patients. The HeartFlow FFRCT Analysis starts when a patient undergoes a standard coronary computed tomography scan at a hospital or imaging center. The CT images are securely uploaded to our cloud. Next, we use advanced algorithms incorporating artificial intelligence to build a personalized, digital model of that patient’s coronary arteries. Our team of highly trained analysts then inspects this model, making any needed edits. Once this patient-specific model is completed, the HeartFlow pathway applies physiologic principles and computational fluid dynamics to compute the blood flow and FFRCT values at every point in the model. Throughout the process, we follow rigorous and well-established protocols to ensure consistent processing for every patient.
Learn more
Infervision
Infervision is a leading AI medical technology company established in 2016, focusing on improving multidisciplinary services and operations with AI. They offer cutting-edge AI products that support medical professionals in all areas, from disease screening and diagnosis to intervention and treatment, patient management, and medical research. Their solutions include InferRead CT Lung for lung nodule detection from chest CT, InferRead DR Chest for detecting chest abnormalities from chest X-rays, InferRead CT Coronary for identifying coronary artery stenosis in coronary CTA, InferRead CT Stroke for triaging hemorrhage from brain CT, InferRead CT Bone for identifying chest fractures from chest CT, and InferRead CT Pneumonia for identifying and triaging pneumonia from chest CT. Additionally, they offer InferOperate for 3D reconstruction in thoracic, liver, and urological surgeries, InferCare for patient management and image follow-up, and InferScholar as an AI-enabled medical research tool.
Learn more
